The RNA‐seq analysis and subsequent GSEA results (Figure 5I,J) further bolstered the aforementioned conclusions, providing additional validation for the efficacy of combining Gefitinib with WntSI in EGFR mutant lung cancer tumors exhibiting MET overexpression/amplification. The gene discussed is MET; the disease is lung carcinoma.